Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 134 Carcinoma, Non-Small-Cell Lung 133 Prostatic Neoplasms 87 Lung Neoplasms 43 Neoplasms 31 Squamous Cell Carcinoma of Head and Neck 30 Neoplasm Metastasis 30 Stomach Neoplasms 26 Head and Neck Neoplasms 24 Esophageal Neoplasms 20 Parkinson Disease 4, Autosomal Dominant Lewy Body 17 Pancreatic Neoplasms 17 Ovarian Neoplasms 16 Urinary Bladder Neoplasms 13 Sarcoma 12 Adenocarcinoma of Lung 9 Triple Negative Breast Neoplasms 8 Fallopian Tube Neoplasms 8 Carcinoma, Transitional Cell 8 Carcinoma, Ovarian Epithelial 8 Adenocarcinoma Of Esophagus 7 Recurrence 6 Carcinoma 6 Inflammatory Breast Neoplasms 5 Carcinoma, Squamous Cell 5 Breast Neoplasms, Male 5 Adenocarcinoma, Bronchiolo-Alveolar 5 Adenocarcinoma 5 Laryngeal Neoplasms 4 Esophageal Squamous Cell Carcinoma 4

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 enfortumab vedotin 1 avelumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Docetaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Urothelial Cancer × Docetaxel × Clear all

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡